APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-Insulin Hypoglycemic Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Non-Insulin Hypoglycemic Drug Market Analysis and Forecast 2026-2032

30 December 2025207 pages

Choose your research edition.

Industry ResearchNon-Insulin Hypoglycemic Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-Insulin Hypoglycemic Drug Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Non-Insulin Hypoglycemic Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-Insulin Hypoglycemic Drug Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-Insulin Hypoglycemic Drug Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Non-Insulin Hypoglycemic Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Non-Insulin Hypoglycemic Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Non-Insulin Hypoglycemic Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Non-Insulin Hypoglycemic Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Non-Insulin Hypoglycemic Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Non-Insulin Hypoglycemic Drug include GSK, Takeda, Merck, Uni-Bio Science Group, Eli Lilly, Jiangsu Hengrui Medicine, Jiangsu Hansoh Pharmaceutical, Pfizer and Sumitomo Dainippon Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Non-Insulin Hypoglycemic Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Non-Insulin Hypoglycemic Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Non-Insulin Hypoglycemic Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Non-Insulin Hypoglycemic Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Non-Insulin Hypoglycemic Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Non-Insulin Hypoglycemic Drug sales, projected growth trends, production technology, application and end-user industry.

Non-Insulin Hypoglycemic Drug Segment by Company

GSK

Takeda

Merck

Uni-Bio Science Group

Eli Lilly

Jiangsu Hengrui Medicine

Jiangsu Hansoh Pharmaceutical

Pfizer

Sumitomo Dainippon Pharma

Servier

Novo Nordisk

Luye Pharma Group

Intarcia Therapeutics

Geropharm

Eurofarma

Emisphere

Dong-A Pharmaceutical

Alkem Labs

3SBio

Non-Insulin Hypoglycemic Drug Segment by Type

Alpha Glucosidase Inhibitors

Meglitinides

Sulfonylureas

Thiazolidinediones

Biguanides

Others

Non-Insulin Hypoglycemic Drug Segment by Application

Hospital Pharmacies

Retail Pharmacies

Non-Insulin Hypoglycemic Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-Insulin Hypoglycemic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-Insulin Hypoglycemic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-Insulin Hypoglycemic Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Non-Insulin Hypoglycemic Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Non-Insulin Hypoglycemic Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non-Insulin Hypoglycemic Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Non-Insulin Hypoglycemic Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Alpha Glucosidase Inhibitors Major Manufacturers Table 3. Meglitinides Major Manufacturers Table 4. Sulfonylureas Major Manufacturers Table 5. Thiazolidinediones Major Manufacturers Table 6. Biguanides Major Manufacturers Table 7. Others Major Manufacturers Table 8. Global Non-Insulin Hypoglycemic Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Hospital Pharmacies Major Manufacturers Table 10. Retail Pharmacies Major Manufacturers Table 11. Non-Insulin Hypoglycemic Drug Industry Trends Table 12. Non-Insulin Hypoglycemic Drug Industry Drivers Table 13. Non-Insulin Hypoglycemic Drug Industry Opportunities and Challenges Table 14. Non-Insulin Hypoglycemic Drug Industry Restraints Table 15. Global Non-Insulin Hypoglycemic Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Non-Insulin Hypoglycemic Drug Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Non-Insulin Hypoglycemic Drug Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2021-2026) Table 19. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2027-2032) Table 20. Global Non-Insulin Hypoglycemic Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 21. Global Non-Insulin Hypoglycemic Drug Sales by Region (2021-2026) & (K Units) Table 22. Global Non-Insulin Hypoglycemic Drug Sales by Region (2027-2032) & (K Units) Table 23. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2021-2026) Table 24. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2027-2032) Table 25. Global Non-Insulin Hypoglycemic Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Non-Insulin Hypoglycemic Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Manufacturers (2021-2026) Table 29. Global Non-Insulin Hypoglycemic Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 30. Global Non-Insulin Hypoglycemic Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Non-Insulin Hypoglycemic Drug Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Non-Insulin Hypoglycemic Drug Manufacturers, Product Type & Application Table 33. Global Non-Insulin Hypoglycemic Drug Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Non-Insulin Hypoglycemic Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Non-Insulin Hypoglycemic Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Non-Insulin Hypoglycemic Drug Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Non-Insulin Hypoglycemic Drug Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2021-2026) Table 40. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2027-2032) Table 41. Global Non-Insulin Hypoglycemic Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 42. Global Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (K Units) Table 43. Global Non-Insulin Hypoglycemic Drug Sales by Type (2027-2032) & (K Units) Table 44. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2021-2026) Table 45. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2027-2032) Table 46. Global Non-Insulin Hypoglycemic Drug Price by Type (2021-2026) & (US$/Unit) Table 47. Global Non-Insulin Hypoglycemic Drug Price by Type (2027-2032) & (US$/Unit) Table 48. Global Non-Insulin Hypoglycemic Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Non-Insulin Hypoglycemic Drug Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Non-Insulin Hypoglycemic Drug Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2021-2026) Table 52. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2027-2032) Table 53. Global Non-Insulin Hypoglycemic Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 54. Global Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (K Units) Table 55. Global Non-Insulin Hypoglycemic Drug Sales by Application (2027-2032) & (K Units) Table 56. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2021-2026) Table 57. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2027-2032) Table 58. Global Non-Insulin Hypoglycemic Drug Price by Application (2021-2026) & (US$/Unit) Table 59. Global Non-Insulin Hypoglycemic Drug Price by Application (2027-2032) & (US$/Unit) Table 60. GSK Company Information Table 61. GSK Business Overview Table 62. GSK Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 63. GSK Non-Insulin Hypoglycemic Drug Product Portfolio Table 64. GSK Recent Development Table 65. Takeda Company Information Table 66. Takeda Business Overview Table 67. Takeda Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Takeda Non-Insulin Hypoglycemic Drug Product Portfolio Table 69. Takeda Recent Development Table 70. Merck Company Information Table 71. Merck Business Overview Table 72. Merck Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Merck Non-Insulin Hypoglycemic Drug Product Portfolio Table 74. Merck Recent Development Table 75. Uni-Bio Science Group Company Information Table 76. Uni-Bio Science Group Business Overview Table 77. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Portfolio Table 79. Uni-Bio Science Group Recent Development Table 80. Eli Lilly Company Information Table 81. Eli Lilly Business Overview Table 82. Eli Lilly Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Eli Lilly Non-Insulin Hypoglycemic Drug Product Portfolio Table 84. Eli Lilly Recent Development Table 85. Jiangsu Hengrui Medicine Company Information Table 86. Jiangsu Hengrui Medicine Business Overview Table 87. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Portfolio Table 89. Jiangsu Hengrui Medicine Recent Development Table 90. Jiangsu Hansoh Pharmaceutical Company Information Table 91. Jiangsu Hansoh Pharmaceutical Business Overview Table 92. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio Table 94. Jiangsu Hansoh Pharmaceutical Recent Development Table 95. Pfizer Company Information Table 96. Pfizer Business Overview Table 97. Pfizer Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Pfizer Non-Insulin Hypoglycemic Drug Product Portfolio Table 99. Pfizer Recent Development Table 100. Sumitomo Dainippon Pharma Company Information Table 101. Sumitomo Dainippon Pharma Business Overview Table 102. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Portfolio Table 104. Sumitomo Dainippon Pharma Recent Development Table 105. Servier Company Information Table 106. Servier Business Overview Table 107. Servier Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Servier Non-Insulin Hypoglycemic Drug Product Portfolio Table 109. Servier Recent Development Table 110. Novo Nordisk Company Information Table 111. Novo Nordisk Business Overview Table 112. Novo Nordisk Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Novo Nordisk Non-Insulin Hypoglycemic Drug Product Portfolio Table 114. Novo Nordisk Recent Development Table 115. Luye Pharma Group Company Information Table 116. Luye Pharma Group Business Overview Table 117. Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Portfolio Table 119. Luye Pharma Group Recent Development Table 120. Intarcia Therapeutics Company Information Table 121. Intarcia Therapeutics Business Overview Table 122. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Portfolio Table 124. Intarcia Therapeutics Recent Development Table 125. Geropharm Company Information Table 126. Geropharm Business Overview Table 127. Geropharm Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Geropharm Non-Insulin Hypoglycemic Drug Product Portfolio Table 129. Geropharm Recent Development Table 130. Eurofarma Company Information Table 131. Eurofarma Business Overview Table 132. Eurofarma Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Eurofarma Non-Insulin Hypoglycemic Drug Product Portfolio Table 134. Eurofarma Recent Development Table 135. Emisphere Company Information Table 136. Emisphere Business Overview Table 137. Emisphere Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Emisphere Non-Insulin Hypoglycemic Drug Product Portfolio Table 139. Emisphere Recent Development Table 140. Dong-A Pharmaceutical Company Information Table 141. Dong-A Pharmaceutical Business Overview Table 142. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio Table 144. Dong-A Pharmaceutical Recent Development Table 145. Alkem Labs Company Information Table 146. Alkem Labs Business Overview Table 147. Alkem Labs Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Alkem Labs Non-Insulin Hypoglycemic Drug Product Portfolio Table 149. Alkem Labs Recent Development Table 150. 3SBio Company Information Table 151. 3SBio Business Overview Table 152. 3SBio Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. 3SBio Non-Insulin Hypoglycemic Drug Product Portfolio Table 154. 3SBio Recent Development Table 155. North America Non-Insulin Hypoglycemic Drug Revenue by Type (2021-2026) & (US$ Million) Table 156. North America Non-Insulin Hypoglycemic Drug Revenue by Type (2027-2032) & (US$ Million) Table 157. North America Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (K Units) Table 158. North America Non-Insulin Hypoglycemic Drug Sales by Type (2027-2032) & (K Units) Table 159. North America Non-Insulin Hypoglycemic Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 160. North America Non-Insulin Hypoglycemic Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 161. North America Non-Insulin Hypoglycemic Drug Revenue by Application (2021-2026) & (US$ Million) Table 162. North America Non-Insulin Hypoglycemic Drug Revenue by Application (2027-2032) & (US$ Million) Table 163. North America Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (K Units) Table 164. North America Non-Insulin Hypoglycemic Drug Sales by Application (2027-2032) & (K Units) Table 165. North America Non-Insulin Hypoglycemic Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 166. North America Non-Insulin Hypoglycemic Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 167. North America Non-Insulin Hypoglycemic Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 168. North America Non-Insulin Hypoglycemic Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 169. North America Non-Insulin Hypoglycemic Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 170. North America Non-Insulin Hypoglycemic Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 171. North America Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units) Table 172. North America Non-Insulin Hypoglycemic Drug Sales by Country (2027-2032) & (K Units) Table 173. North America Non-Insulin Hypoglycemic Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 174. North America Non-Insulin Hypoglycemic Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 175. United States Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 176. Canada Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 177. Europe Non-Insulin Hypoglycemic Drug Revenue by Type (2021-2026) & (US$ Million) Table 178. Europe Non-Insulin Hypoglycemic Drug Revenue by Type (2027-2032) & (US$ Million) Table 179. Europe Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (K Units) Table 180. Europe Non-Insulin Hypoglycemic Drug Sales by Type (2027-2032) & (K Units) Table 181. Europe Non-Insulin Hypoglycemic Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 182. Europe Non-Insulin Hypoglycemic Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 183. Europe Non-Insulin Hypoglycemic Drug Revenue by Application (2021-2026) & (US$ Million) Table 184. Europe Non-Insulin Hypoglycemic Drug Revenue by Application (2027-2032) & (US$ Million) Table 185. Europe Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (K Units) Table 186. Europe Non-Insulin Hypoglycemic Drug Sales by Application (2027-2032) & (K Units) Table 187. Europe Non-Insulin Hypoglycemic Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 188. Europe Non-Insulin Hypoglycemic Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 189. Europe Non-Insulin Hypoglycemic Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 190. Europe Non-Insulin Hypoglycemic Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 191. Europe Non-Insulin Hypoglycemic Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 192. Europe Non-Insulin Hypoglycemic Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 193. Europe Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units) Table 194. Europe Non-Insulin Hypoglycemic Drug Sales by Country (2027-2032) & (K Units) Table 195. Europe Non-Insulin Hypoglycemic Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 196. Europe Non-Insulin Hypoglycemic Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 197. Germany Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 198. France Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 199. U.K. Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 200. Italy Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 201. Netherlands Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 202. China Non-Insulin Hypoglycemic Drug Revenue by Type (2021-2026) & (US$ Million) Table 203. China Non-Insulin Hypoglycemic Drug Revenue by Type (2027-2032) & (US$ Million) Table 204. China Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (K Units) Table 205. China Non-Insulin Hypoglycemic Drug Sales by Type (2027-2032) & (K Units) Table 206. China Non-Insulin Hypoglycemic Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 207. China Non-Insulin Hypoglycemic Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 208. China Non-Insulin Hypoglycemic Drug Revenue by Application (2021-2026) & (US$ Million) Table 209. China Non-Insulin Hypoglycemic Drug Revenue by Application (2027-2032) & (US$ Million) Table 210. China Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (K Units) Table 211. China Non-Insulin Hypoglycemic Drug Sales by Application (2027-2032) & (K Units) Table 212. China Non-Insulin Hypoglycemic Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 213. China Non-Insulin Hypoglycemic Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 214. Asia Non-Insulin Hypoglycemic Drug Revenue by Type (2021-2026) & (US$ Million) Table 215. Asia Non-Insulin Hypoglycemic Drug Revenue by Type (2027-2032) & (US$ Million) Table 216. Asia Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (K Units) Table 217. Asia Non-Insulin Hypoglycemic Drug Sales by Type (2027-2032) & (K Units) Table 218. Asia Non-Insulin Hypoglycemic Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 219. Asia Non-Insulin Hypoglycemic Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 220. Asia Non-Insulin Hypoglycemic Drug Revenue by Application (2021-2026) & (US$ Million) Table 221. Asia Non-Insulin Hypoglycemic Drug Revenue by Application (2027-2032) & (US$ Million) Table 222. Asia Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (K Units) Table 223. Asia Non-Insulin Hypoglycemic Drug Sales by Application (2027-2032) & (K Units) Table 224. Asia Non-Insulin Hypoglycemic Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 225. Asia Non-Insulin Hypoglycemic Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 226. Asia Non-Insulin Hypoglycemic Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 227. Asia Non-Insulin Hypoglycemic Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 228. Asia Non-Insulin Hypoglycemic Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 229. Asia Non-Insulin Hypoglycemic Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 230. Asia Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units) Table 231. Asia Non-Insulin Hypoglycemic Drug Sales by Country (2027-2032) & (K Units) Table 232. Asia Non-Insulin Hypoglycemic Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 233. Asia Non-Insulin Hypoglycemic Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 234. Japan Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 235. South Korea Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 236. India Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 237. Australia Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 238. China Taiwan Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 239. Southeast Asia Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 240. SAMEA Non-Insulin Hypoglycemic Drug Revenue by Type (2021-2026) & (US$ Million) Table 241. SAMEA Non-Insulin Hypoglycemic Drug Revenue by Type (2027-2032) & (US$ Million) Table 242. SAMEA Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (K Units) Table 243. SAMEA Non-Insulin Hypoglycemic Drug Sales by Type (2027-2032) & (K Units) Table 244. SAMEA Non-Insulin Hypoglycemic Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 245. SAMEA Non-Insulin Hypoglycemic Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 246. SAMEA Non-Insulin Hypoglycemic Drug Revenue by Application (2021-2026) & (US$ Million) Table 247. SAMEA Non-Insulin Hypoglycemic Drug Revenue by Application (2027-2032) & (US$ Million) Table 248. SAMEA Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (K Units) Table 249. SAMEA Non-Insulin Hypoglycemic Drug Sales by Application (2027-2032) & (K Units) Table 250. SAMEA Non-Insulin Hypoglycemic Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 251. SAMEA Non-Insulin Hypoglycemic Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 252. SAMEA Non-Insulin Hypoglycemic Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 253. SAMEA Non-Insulin Hypoglycemic Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 254. SAMEA Non-Insulin Hypoglycemic Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 255. SAMEA Non-Insulin Hypoglycemic Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 256. SAMEA Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units) Table 257. SAMEA Non-Insulin Hypoglycemic Drug Sales by Country (2027-2032) & (K Units) Table 258. SAMEA Non-Insulin Hypoglycemic Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 259. SAMEA Non-Insulin Hypoglycemic Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 260. Brazil Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 261. Argentina Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 262. Chile Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 263. Colombia Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 264. Peru Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 265. Saudi Arabia Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 266. Israel Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 267. UAE Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 268. Turkey Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 269. Iran Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 270. Egypt Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Table 271. Key Raw Materials Table 272. Raw Materials Key Suppliers Table 273. Non-Insulin Hypoglycemic Drug Distributors List Table 274. Non-Insulin Hypoglycemic Drug Customers List Table 275. Research Programs/Design for This Report Table 276. Authors List of This Report Table 277. Secondary Sources Table 278. Primary Sources List of Figures Figure 1. Non-Insulin Hypoglycemic Drug Image Figure 2. Global Non-Insulin Hypoglycemic Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-Insulin Hypoglycemic Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Alpha Glucosidase Inhibitors Image Figure 5. Meglitinides Image Figure 6. Sulfonylureas Image Figure 7. Thiazolidinediones Image Figure 8. Biguanides Image Figure 9. Others Image Figure 10. Global Non-Insulin Hypoglycemic Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Non-Insulin Hypoglycemic Drug Market Size Share 2021 VS 2025 VS 2032 Figure 12. Hospital Pharmacies Image Figure 13. Retail Pharmacies Image Figure 14. Global Non-Insulin Hypoglycemic Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million) Figure 16. Global Non-Insulin Hypoglycemic Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2021-2032) Figure 19. Global Non-Insulin Hypoglycemic Drug Sales (2021-2032) & (K Units) Figure 20. Global Non-Insulin Hypoglycemic Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 21. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Non-Insulin Hypoglycemic Drug Sales YoY (2021-2032) & (K Units) Figure 23. Europe Non-Insulin Hypoglycemic Drug Sales YoY (2021-2032) & (K Units) Figure 24. China Non-Insulin Hypoglycemic Drug Sales YoY (2021-2032) & (K Units) Figure 25. Asia (Excluding China) Non-Insulin Hypoglycemic Drug Sales YoY (2021-2032) & (K Units) Figure 26. South America, Middle East and Africa Non-Insulin Hypoglycemic Drug Sales YoY (2021-2032) & (K Units) Figure 27. Global Non-Insulin Hypoglycemic Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Non-Insulin Hypoglycemic Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Non-Insulin Hypoglycemic Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2021-2032) Figure 33. Global Non-Insulin Hypoglycemic Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 34. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2021-2032) Figure 36. Global Non-Insulin Hypoglycemic Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2021-2032) Figure 39. Global Non-Insulin Hypoglycemic Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 40. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2021-2032) Figure 42. North America Non-Insulin Hypoglycemic Drug Revenue Share by Type (2021-2032) Figure 43. North America Non-Insulin Hypoglycemic Drug Sales Share by Type (2021-2032) Figure 44. North America Non-Insulin Hypoglycemic Drug Revenue Share by Application (2021-2032) Figure 45. North America Non-Insulin Hypoglycemic Drug Sales Share by Application (2021-2032) Figure 46. North America Non-Insulin Hypoglycemic Drug Revenue Share by Country (2021-2032) Figure 47. North America Non-Insulin Hypoglycemic Drug Sales Share by Country (2021-2032) Figure 48. Europe Non-Insulin Hypoglycemic Drug Revenue Share by Type (2021-2032) Figure 49. Europe Non-Insulin Hypoglycemic Drug Sales Share by Type (2021-2032) Figure 50. Europe Non-Insulin Hypoglycemic Drug Revenue Share by Application (2021-2032) Figure 51. Europe Non-Insulin Hypoglycemic Drug Sales Share by Application (2021-2032) Figure 52. Europe Non-Insulin Hypoglycemic Drug Revenue Share by Country (2021-2032) Figure 53. Europe Non-Insulin Hypoglycemic Drug Sales Share by Country (2021-2032) Figure 54. China Non-Insulin Hypoglycemic Drug Revenue Share by Type (2021-2032) Figure 55. China Non-Insulin Hypoglycemic Drug Sales Share by Type (2021-2032) Figure 56. China Non-Insulin Hypoglycemic Drug Revenue Share by Application (2021-2032) Figure 57. China Non-Insulin Hypoglycemic Drug Sales Share by Application (2021-2032) Figure 58. Asia Non-Insulin Hypoglycemic Drug Revenue Share by Type (2021-2032) Figure 59. Asia Non-Insulin Hypoglycemic Drug Sales Share by Type (2021-2032) Figure 60. Asia Non-Insulin Hypoglycemic Drug Revenue Share by Application (2021-2032) Figure 61. Asia Non-Insulin Hypoglycemic Drug Sales Share by Application (2021-2032) Figure 62. Asia Non-Insulin Hypoglycemic Drug Revenue Share by Country (2021-2032) Figure 63. Asia Non-Insulin Hypoglycemic Drug Sales Share by Country (2021-2032) Figure 64. SAMEA Non-Insulin Hypoglycemic Drug Revenue Share by Type (2021-2032) Figure 65. SAMEA Non-Insulin Hypoglycemic Drug Sales Share by Type (2021-2032) Figure 66. SAMEA Non-Insulin Hypoglycemic Drug Revenue Share by Application (2021-2032) Figure 67. SAMEA Non-Insulin Hypoglycemic Drug Sales Share by Application (2021-2032) Figure 68. SAMEA Non-Insulin Hypoglycemic Drug Revenue Share by Country (2021-2032) Figure 69. SAMEA Non-Insulin Hypoglycemic Drug Sales Share by Country (2021-2032) Figure 70. Non-Insulin Hypoglycemic Drug Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Non-Insulin Hypoglycemic Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Alpha Glucosidase Inhibitors
  • Meglitinides
  • Sulfonylureas
  • Thiazolidinediones
  • Biguanides
  • Others
Applications
  • Hospital Pharmacies
  • Retail Pharmacies
Companies covered
  • GSK
  • Takeda
  • Merck
  • Uni-Bio Science Group
  • Eli Lilly
  • Jiangsu Hengrui Medicine
  • Jiangsu Hansoh Pharmaceutical
  • Pfizer
  • Sumitomo Dainippon Pharma
  • Servier
  • Novo Nordisk
  • Luye Pharma Group
  • Intarcia Therapeutics
  • Geropharm
  • Eurofarma
  • Emisphere
  • Dong-A Pharmaceutical
  • Alkem Labs
  • 3SBio

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Non-Insulin Hypoglycemic Drug Market by Type
  3. 1.2.1 Global Non-Insulin Hypoglycemic Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Alpha Glucosidase Inhibitors
  5. 1.2.3 Meglitinides
  6. 1.2.4 Sulfonylureas
  7. 1.2.5 Thiazolidinediones
  8. 1.2.6 Biguanides
  9. 1.2.7 Others
  10. 1.3 Non-Insulin Hypoglycemic Drug Market by Application
  11. 1.3.1 Global Non-Insulin Hypoglycemic Drug Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Hospital Pharmacies
  13. 1.3.3 Retail Pharmacies
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Non-Insulin Hypoglycemic Drug Market Dynamics
  1. 2.1 Non-Insulin Hypoglycemic Drug Industry Trends
  2. 2.2 Non-Insulin Hypoglycemic Drug Industry Drivers
  3. 2.3 Non-Insulin Hypoglycemic Drug Industry Opportunities and Challenges
  4. 2.4 Non-Insulin Hypoglycemic Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Non-Insulin Hypoglycemic Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Non-Insulin Hypoglycemic Drug Revenue by Region
  3. 3.2.1 Global Non-Insulin Hypoglycemic Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Non-Insulin Hypoglycemic Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Non-Insulin Hypoglycemic Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Non-Insulin Hypoglycemic Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Non-Insulin Hypoglycemic Drug Sales by Region
  9. 3.4.1 Global Non-Insulin Hypoglycemic Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Non-Insulin Hypoglycemic Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Non-Insulin Hypoglycemic Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Non-Insulin Hypoglycemic Drug Revenue by Manufacturers
  2. 4.1.1 Global Non-Insulin Hypoglycemic Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Non-Insulin Hypoglycemic Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Non-Insulin Hypoglycemic Drug Sales by Manufacturers
  6. 4.2.1 Global Non-Insulin Hypoglycemic Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Non-Insulin Hypoglycemic Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Non-Insulin Hypoglycemic Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Non-Insulin Hypoglycemic Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Non-Insulin Hypoglycemic Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Non-Insulin Hypoglycemic Drug Manufacturers, Product Type & Application
  13. 4.7 Global Non-Insulin Hypoglycemic Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Non-Insulin Hypoglycemic Drug Market CR5 and HHI
  16. 4.8.2 2025 Non-Insulin Hypoglycemic Drug Tier 1, Tier 2, and Tier 3
5 Non-Insulin Hypoglycemic Drug Market by Type
  1. 5.1 Global Non-Insulin Hypoglycemic Drug Revenue by Type
  2. 5.1.1 Global Non-Insulin Hypoglycemic Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Non-Insulin Hypoglycemic Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Non-Insulin Hypoglycemic Drug Sales by Type
  6. 5.2.1 Global Non-Insulin Hypoglycemic Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Non-Insulin Hypoglycemic Drug Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Non-Insulin Hypoglycemic Drug Price by Type
6 Non-Insulin Hypoglycemic Drug Market by Application
  1. 6.1 Global Non-Insulin Hypoglycemic Drug Revenue by Application
  2. 6.1.1 Global Non-Insulin Hypoglycemic Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Non-Insulin Hypoglycemic Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Non-Insulin Hypoglycemic Drug Sales by Application
  6. 6.2.1 Global Non-Insulin Hypoglycemic Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Non-Insulin Hypoglycemic Drug Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Non-Insulin Hypoglycemic Drug Price by Application
7 Company Profiles
  1. 7.1 GSK
  2. 7.1.1 GSK Company Information
  3. 7.1.2 GSK Business Overview
  4. 7.1.3 GSK Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 GSK Non-Insulin Hypoglycemic Drug Product Portfolio
  6. 7.1.5 GSK Recent Developments
  7. 7.2 Takeda
  8. 7.2.1 Takeda Company Information
  9. 7.2.2 Takeda Business Overview
  10. 7.2.3 Takeda Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Takeda Non-Insulin Hypoglycemic Drug Product Portfolio
  12. 7.2.5 Takeda Recent Developments
  13. 7.3 Merck
  14. 7.3.1 Merck Company Information
  15. 7.3.2 Merck Business Overview
  16. 7.3.3 Merck Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Merck Non-Insulin Hypoglycemic Drug Product Portfolio
  18. 7.3.5 Merck Recent Developments
  19. 7.4 Uni-Bio Science Group
  20. 7.4.1 Uni-Bio Science Group Company Information
  21. 7.4.2 Uni-Bio Science Group Business Overview
  22. 7.4.3 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Portfolio
  24. 7.4.5 Uni-Bio Science Group Recent Developments
  25. 7.5 Eli Lilly
  26. 7.5.1 Eli Lilly Company Information
  27. 7.5.2 Eli Lilly Business Overview
  28. 7.5.3 Eli Lilly Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Eli Lilly Non-Insulin Hypoglycemic Drug Product Portfolio
  30. 7.5.5 Eli Lilly Recent Developments
  31. 7.6 Jiangsu Hengrui Medicine
  32. 7.6.1 Jiangsu Hengrui Medicine Company Information
  33. 7.6.2 Jiangsu Hengrui Medicine Business Overview
  34. 7.6.3 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Portfolio
  36. 7.6.5 Jiangsu Hengrui Medicine Recent Developments
  37. 7.7 Jiangsu Hansoh Pharmaceutical
  38. 7.7.1 Jiangsu Hansoh Pharmaceutical Company Information
  39. 7.7.2 Jiangsu Hansoh Pharmaceutical Business Overview
  40. 7.7.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio
  42. 7.7.5 Jiangsu Hansoh Pharmaceutical Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Non-Insulin Hypoglycemic Drug Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
  49. 7.9 Sumitomo Dainippon Pharma
  50. 7.9.1 Sumitomo Dainippon Pharma Company Information
  51. 7.9.2 Sumitomo Dainippon Pharma Business Overview
  52. 7.9.3 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Portfolio
  54. 7.9.5 Sumitomo Dainippon Pharma Recent Developments
  55. 7.10 Servier
  56. 7.10.1 Servier Company Information
  57. 7.10.2 Servier Business Overview
  58. 7.10.3 Servier Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Servier Non-Insulin Hypoglycemic Drug Product Portfolio
  60. 7.10.5 Servier Recent Developments
  61. 7.11 Novo Nordisk
  62. 7.11.1 Novo Nordisk Company Information
  63. 7.11.2 Novo Nordisk Business Overview
  64. 7.11.3 Novo Nordisk Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Novo Nordisk Non-Insulin Hypoglycemic Drug Product Portfolio
  66. 7.11.5 Novo Nordisk Recent Developments
  67. 7.12 Luye Pharma Group
  68. 7.12.1 Luye Pharma Group Company Information
  69. 7.12.2 Luye Pharma Group Business Overview
  70. 7.12.3 Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Portfolio
  72. 7.12.5 Luye Pharma Group Recent Developments
  73. 7.13 Intarcia Therapeutics
  74. 7.13.1 Intarcia Therapeutics Company Information
  75. 7.13.2 Intarcia Therapeutics Business Overview
  76. 7.13.3 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Portfolio
  78. 7.13.5 Intarcia Therapeutics Recent Developments
  79. 7.14 Geropharm
  80. 7.14.1 Geropharm Company Information
  81. 7.14.2 Geropharm Business Overview
  82. 7.14.3 Geropharm Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Geropharm Non-Insulin Hypoglycemic Drug Product Portfolio
  84. 7.14.5 Geropharm Recent Developments
  85. 7.15 Eurofarma
  86. 7.15.1 Eurofarma Company Information
  87. 7.15.2 Eurofarma Business Overview
  88. 7.15.3 Eurofarma Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Eurofarma Non-Insulin Hypoglycemic Drug Product Portfolio
  90. 7.15.5 Eurofarma Recent Developments
  91. 7.16 Emisphere
  92. 7.16.1 Emisphere Company Information
  93. 7.16.2 Emisphere Business Overview
  94. 7.16.3 Emisphere Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Emisphere Non-Insulin Hypoglycemic Drug Product Portfolio
  96. 7.16.5 Emisphere Recent Developments
  97. 7.17 Dong-A Pharmaceutical
  98. 7.17.1 Dong-A Pharmaceutical Company Information
  99. 7.17.2 Dong-A Pharmaceutical Business Overview
  100. 7.17.3 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio
  102. 7.17.5 Dong-A Pharmaceutical Recent Developments
  103. 7.18 Alkem Labs
  104. 7.18.1 Alkem Labs Company Information
  105. 7.18.2 Alkem Labs Business Overview
  106. 7.18.3 Alkem Labs Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Alkem Labs Non-Insulin Hypoglycemic Drug Product Portfolio
  108. 7.18.5 Alkem Labs Recent Developments
  109. 7.19 3SBio
  110. 7.19.1 3SBio Company Information
  111. 7.19.2 3SBio Business Overview
  112. 7.19.3 3SBio Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 3SBio Non-Insulin Hypoglycemic Drug Product Portfolio
  114. 7.19.5 3SBio Recent Developments
8 North America
  1. 8.1 North America Non-Insulin Hypoglycemic Drug Market Size by Type
  2. 8.1.1 North America Non-Insulin Hypoglycemic Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Non-Insulin Hypoglycemic Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Non-Insulin Hypoglycemic Drug Price by Type (2021-2032)
  5. 8.2 North America Non-Insulin Hypoglycemic Drug Market Size by Application
  6. 8.2.1 North America Non-Insulin Hypoglycemic Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Non-Insulin Hypoglycemic Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Non-Insulin Hypoglycemic Drug Price by Application (2021-2032)
  9. 8.3 North America Non-Insulin Hypoglycemic Drug Market Size by Country
  10. 8.3.1 North America Non-Insulin Hypoglycemic Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Non-Insulin Hypoglycemic Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Non-Insulin Hypoglycemic Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Non-Insulin Hypoglycemic Drug Market Size by Type
  2. 9.1.1 Europe Non-Insulin Hypoglycemic Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Non-Insulin Hypoglycemic Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Non-Insulin Hypoglycemic Drug Price by Type (2021-2032)
  5. 9.2 Europe Non-Insulin Hypoglycemic Drug Market Size by Application
  6. 9.2.1 Europe Non-Insulin Hypoglycemic Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Non-Insulin Hypoglycemic Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Non-Insulin Hypoglycemic Drug Price by Application (2021-2032)
  9. 9.3 Europe Non-Insulin Hypoglycemic Drug Market Size by Country
  10. 9.3.1 Europe Non-Insulin Hypoglycemic Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Non-Insulin Hypoglycemic Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Non-Insulin Hypoglycemic Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Non-Insulin Hypoglycemic Drug Market Size by Type
  2. 10.1.1 China Non-Insulin Hypoglycemic Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Non-Insulin Hypoglycemic Drug Sales by Type (2021-2032)
  4. 10.1.3 China Non-Insulin Hypoglycemic Drug Price by Type (2021-2032)
  5. 10.2 China Non-Insulin Hypoglycemic Drug Market Size by Application
  6. 10.2.1 China Non-Insulin Hypoglycemic Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Non-Insulin Hypoglycemic Drug Sales by Application (2021-2032)
  8. 10.2.3 China Non-Insulin Hypoglycemic Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Non-Insulin Hypoglycemic Drug Market Size by Type
  2. 11.1.1 Asia Non-Insulin Hypoglycemic Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Non-Insulin Hypoglycemic Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Non-Insulin Hypoglycemic Drug Price by Type (2021-2032)
  5. 11.2 Asia Non-Insulin Hypoglycemic Drug Market Size by Application
  6. 11.2.1 Asia Non-Insulin Hypoglycemic Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Non-Insulin Hypoglycemic Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Non-Insulin Hypoglycemic Drug Price by Application (2021-2032)
  9. 11.3 Asia Non-Insulin Hypoglycemic Drug Market Size by Country
  10. 11.3.1 Asia Non-Insulin Hypoglycemic Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Non-Insulin Hypoglycemic Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Non-Insulin Hypoglycemic Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Non-Insulin Hypoglycemic Drug Market Size by Type
  2. 12.1.1 SAMEA Non-Insulin Hypoglycemic Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Non-Insulin Hypoglycemic Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Non-Insulin Hypoglycemic Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Non-Insulin Hypoglycemic Drug Market Size by Application
  6. 12.2.1 SAMEA Non-Insulin Hypoglycemic Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Non-Insulin Hypoglycemic Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Non-Insulin Hypoglycemic Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Non-Insulin Hypoglycemic Drug Market Size by Country
  10. 12.3.1 SAMEA Non-Insulin Hypoglycemic Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Non-Insulin Hypoglycemic Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Non-Insulin Hypoglycemic Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Non-Insulin Hypoglycemic Drug Value Chain Analysis
  2. 13.1.1 Non-Insulin Hypoglycemic Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Non-Insulin Hypoglycemic Drug Production Mode & Process
  6. 13.2 Non-Insulin Hypoglycemic Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Non-Insulin Hypoglycemic Drug Distributors
  9. 13.2.3 Non-Insulin Hypoglycemic Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst